Sanofi reports positive phase 3 HERCULES study data for tolebrutinib in non-relapsing secondary progressive multiple sclerosis, showing a 31% delay in disability progression. Study also revealed ...
In The Lancet Respiratory Medicine, Olivier Sitbon and colleagues1 present the results of a randomised, phase 2b clinical trial (ELEVATE-2) that compared the safety and efficacy of pulmonary arterial ...